{"id":48879,"date":"2025-03-03T14:14:23","date_gmt":"2025-03-03T13:14:23","guid":{"rendered":"https:\/\/www.bricbordeaux.com\/2025\/03\/lancet-oncology-article-new-anti-androgen-treatment-for-triple-negative-breast-cancer\/"},"modified":"2025-03-04T10:30:25","modified_gmt":"2025-03-04T09:30:25","slug":"lancet-oncology-article-new-anti-androgen-treatment-for-triple-negative-breast-cancer","status":"publish","type":"post","link":"https:\/\/www.bricbordeaux.com\/en\/2025\/03\/lancet-oncology-article-new-anti-androgen-treatment-for-triple-negative-breast-cancer\/","title":{"rendered":"Lancet Oncology article – New anti-androgen treatment for triple-negative breast cancer."},"content":{"rendered":"\n

On this World Triple Negative Breast Cancer Day, we are pleased to congratulate the Team 7 – \u201cTargeting Transcription in Breast Cancer\u201d<\/a><\/strong>, headed by Pr. Martin Teichmann <\/a>, whose work, led by Pr. Richard Iggo <\/a><\/strong> and Pr. Herv\u00e9 Bonnefoi <\/a><\/strong>on a rare form of triple-negative breast cancer has been published in the prestigious Lancet Oncology<\/a><\/strong>. Their work on this rare form of cancer, in which the cancer cells express a high level of the androgen receptor, offers hope of a hormone treatment that is more tolerable than the chemotherapy treatments used to date. Clinical trials have yet to be set up to validate this treatment. <\/p>\n

\n
\"\"
BRIC team 7 – Targeting Transcription in Breast Cancer.<\/figcaption><\/figure>\n<\/div>\n

This work is the fruit of collaboration with researchers and clinicians, mainly in France: Institut Bergoni\u00e9<\/a> (Bordeaux), Institut Paoli-Calmettes<\/a> (Marseille), Institut Curie<\/a> (St Cloud), Centre L\u00e9on B\u00e9rard<\/a> (Lyon), Oncopole Toulouse<\/a>, Institut du Cancer de Montpellier<\/a> and numerous hospital departments (Paris, Quimper, Caen, Villejuif, Orl\u00e9ans, Brest, Clermont-Ferrand, Angers, Charleroi).<\/p>\n\n

Thanks to our supporters and funders: Bayer<\/a>, Europe (Interreg BOTS grant)<\/a>, UniCancer Breast Group (UCBG)<\/a>, Fondation Bergoni\u00e9<\/a>, Fondation Nova (Geneva), La Ligue contre le cancer<\/a> (comit\u00e9 des Landes et comit\u00e9 des Pyr\u00e9n\u00e9es Atlantiques), La Fondation les 3 Roses.<\/p>\n\n

<\/div>\n\n
\n
Read the scientific article<\/a><\/div>\n<\/div>\n\n
<\/div>\n\n

Explanations by Pr. Richard Iggo : <\/h2>\n\n

We proposed in 2005 that androgens replace oestrogens as the driver steroids in a subgroup of triple-negative breast cancer (TNBC) with androgen receptor (AR) expression called molecular apocrine (MA) breast cancer. Here, we report the analysis of a clinical trial evaluating the antitumour activity of the anti-androgen darolutamide in MA breast cancer. Transcriptomic analysis was used to classify tumours into groups with high and low AR activity (MAhi<\/sup> and MAl<\/sup>o<\/sup>). The primary translational endpoint was clinical benefit rate at 16 weeks. In patients treated with darolutamide, the clinical benefit rate was 57%<\/strong> (12 of 21; 95% CI 36\u201378) in MAhi<\/sup> tumours, and 16% (five of 31; 95% CI 3\u201329; p=0\u00b70020) in other tumours. We conclude that high AR activity identifies a subgroup of patients with AR-positive, ER-negative breast cancer who are candidates for treatment with anti-androgens. This means we now have a coherent framework in which to target AR in breast cancer: <\/p>\n\n